CardiLink is exploring the advantages of investing with Asavie IoT Connect for monitoring and maintaining the automatic external defibrillator (AED) devices installed in both public and corporate sectors.
AED owners, as well as manufacturers, will receive critical insights for abiding by the EU and US health sector legislative directives for operational implementation in devices from the cloud platform provided by the CardiLink.
EU and US health sector legislative directives are important for the maintenance of the systems in which AED is installed. These AEDs are cyber-threat-free as they are specially designed for the private network.
Asavie IoT Connect can also be utilised by CardiLink for providing individual manufacturers with on-demand secured private network connectivity. It helps in providing security to private networks and in securing a prominent position in the global medical devices market.
Based in Germany, CardiLink is a medical devices monitoring company, while Asavie IoT Connect is an Ireland-based secure connectivity firm.
Zimmer Biomet and Apple are planning to provide assistance to users of the Apple smartwatch and iPhone to help in knee and hip replacement surgeries.
Zimmer Biomet’s mymobility app installed in the Apple watch will connect the patients to their surgical care teams. The app will also conduct clinical survey based on 10,000 joint replacement patients in the US pertaining to their feedbacks on the result and the cost.
The patients who have undergone a hip or knee surgery will be able to contact the surgeons as well as get recovering tips with the help of the mymobility app. Patient’s feedback will be valued for advancing the app and medical care initiatives.
Based in the US, Zimmer Biomet is a musculoskeletal healthcare company, while Apple, also based in the US, is a multinational technology company.
US-based Cardialen has secured $17m in a series B financing round led by RiverVest Venture Partners.
Several healthcare companies such as HBM Healthcare Investments and Cultivation Capital and Qiming Venture Partners also participated in the financing round.
The fund raised will be used towards the development of clinical unpinning termination (UPT) therapy, which helps in restoring abnormal heart rates by providing a series of low-energy electrical pulses. It will also be used in the development of an implant.